These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 18779044)
41. Verrucous herpes of the finger in a patient with HIV-1 infection. Gonzales Zamora JA; Espinoza LA Infection; 2018 Apr; 46(2):285-286. PubMed ID: 28762202 [No Abstract] [Full Text] [Related]
42. Treatment of HIV infection with drugs for HSV-2 infection. Huttner A; Calmy A Lancet; 2010 Jul; 376(9735):88; author reply 88. PubMed ID: 20621229 [No Abstract] [Full Text] [Related]
43. Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S Adv Exp Med Biol; 1996; 394():59-66. PubMed ID: 8815710 [No Abstract] [Full Text] [Related]
44. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. Rossi L; Brandi G; Schiavano GF; Balestra E; Millo E; Scarfi S; Damonte G; Gasparini A; Magnani M; Perno CF; Benatti U; De Flora A AIDS Res Hum Retroviruses; 1998 Mar; 14(5):435-44. PubMed ID: 9546803 [TBL] [Abstract][Full Text] [Related]
45. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. Balzarini J; Haller-Meier F; De Clercq E; Meier C Antivir Chem Chemother; 2001 Sep; 12(5):301-6. PubMed ID: 11900349 [TBL] [Abstract][Full Text] [Related]
47. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220 [TBL] [Abstract][Full Text] [Related]
48. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? Bollen LJ; Whitehead SJ; Mock PA; Leelawiwat W; Asavapiriyanont S; Chalermchockchareonkit A; Vanprapar N; Chotpitayasunondh T; McNicholl JM; Tappero JW; Shaffer N; Chuachoowong R AIDS; 2008 Jun; 22(10):1169-76. PubMed ID: 18525263 [TBL] [Abstract][Full Text] [Related]
49. Detection of a novel mutation conferring acyclovir resistance and consecutive treatment failure in an HIV-positive patient with recurrent HSV-2 infection. Schleenvoigt BT; Pletz MW; Deinhardt-Emmer S; Sauerbrei A J Glob Antimicrob Resist; 2018 Mar; 12():20. PubMed ID: 29179992 [No Abstract] [Full Text] [Related]
50. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376 [TBL] [Abstract][Full Text] [Related]
51. Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. Corey L J Infect Dis; 2007 May; 195(9):1242-4. PubMed ID: 17396990 [No Abstract] [Full Text] [Related]
52. Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscarnet. Jones TJ; Paul R J Infect Dis; 1995 Feb; 171(2):508-9. PubMed ID: 7844404 [No Abstract] [Full Text] [Related]
53. [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. Losada I; Cañizares A; Hellín T; Martí-Belda P; Guerrero A Enferm Infecc Microbiol Clin; 2002 Jan; 20(1):25-7. PubMed ID: 11820977 [TBL] [Abstract][Full Text] [Related]
54. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520 [TBL] [Abstract][Full Text] [Related]
55. Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy. Péré H; Rascanu A; LeGoff J; Matta M; Bois F; Lortholary O; Leroy V; Launay O; Bélec L; Int J STD AIDS; 2016 Mar; 27(3):178-85. PubMed ID: 25769886 [TBL] [Abstract][Full Text] [Related]